Mimedx (MDXG) Non-Current Assets (2010 - 2026)
Mimedx recorded quarterly Non-Current Assets of $68.4 million in Q1 2026, up 4.86% quarter-over-quarter from $65.2 million in Q4 2025, and down 2.78% year-over-year from $70.3 million in Q1 2025.
Mimedx's Non-Current Assets history runs 17 years deep, the most recent figure standing at $68.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 2.78% year-over-year to $68.4 million; the TTM figure through Mar 2026 stood at $268.7 million (down 7.44% YoY), while the FY2025 annual figure was $65.2 million, down 9.51% from the prior year.
- Non-Current Assets came in at $68.4 million for Q1 2026 at Mimedx, up from $65.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $82.8 million in Q1 2024 to a low of $34.5 million in Q3 2023.
- A 5-year average of $57.2 million and a median of $65.2 million in 2025 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets surged 127.19% in 2024 and decreased 15.12% in 2025, its largest moves.
- Mimedx's Non-Current Assets stood at $37.2 million in 2022, then soared by 100.86% to $74.8 million in 2023, then slipped by 3.69% to $72.0 million in 2024, then fell by 9.51% to $65.2 million in 2025, then climbed by 4.86% to $68.4 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $68.4 million, $65.2 million, and $64.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 68.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.35 Mn |
| Dec 31, 2025 | 65.18 Mn |
| Sep 30, 2025 | 64.89 Mn |
| Jun 30, 2025 | 70.23 Mn |
| Mar 31, 2025 | 70.31 Mn |
| Dec 31, 2024 | 72.03 Mn |
| Sep 30, 2024 | 71.75 Mn |
| Jun 30, 2024 | 76.17 Mn |
| Mar 31, 2024 | 82.83 Mn |
| Dec 31, 2023 | 74.79 Mn |
| Sep 30, 2023 | 34.52 Mn |
| Jun 30, 2023 | 35.16 Mn |
| Mar 31, 2023 | 36.46 Mn |
| Dec 31, 2022 | 37.23 Mn |
| Sep 30, 2022 | 36.76 Mn |
| Jun 30, 2022 | 37.66 Mn |
| Mar 31, 2022 | 38.54 Mn |
| Dec 31, 2021 | 39.41 Mn |
| Sep 30, 2021 | 38.62 Mn |
| Jun 30, 2021 | 39.46 Mn |
| Mar 31, 2021 | 40.85 Mn |
| Dec 31, 2020 | 41.42 Mn |
| Sep 30, 2020 | 41.85 Mn |
| Jun 30, 2020 | 43.31 Mn |
| Mar 31, 2020 | 43.02 Mn |
| Dec 31, 2019 | 43.92 Mn |
| Sep 30, 2019 | 45.27 Mn |
| Jun 30, 2019 | 47.81 Mn |
| Mar 31, 2019 | 50.26 Mn |
| Dec 31, 2018 | 48.80 Mn |
| Dec 31, 2017 | 72.51 Mn |
| Sep 30, 2017 | 64.60 Mn |
| Jun 30, 2017 | 67.32 Mn |
| Mar 31, 2017 | 66.59 Mn |
| Dec 31, 2016 | 57.80 Mn |
| Sep 30, 2016 | 75.38 Mn |
| Jun 30, 2016 | 75.21 Mn |
| Mar 31, 2016 | 81.98 Mn |
| Dec 31, 2015 | 39.60 Mn |
| Sep 30, 2015 | 23.18 Mn |
| Jun 30, 2015 | 22.03 Mn |
| Mar 31, 2015 | 23.82 Mn |
| Dec 31, 2014 | 23.58 Mn |
| Sep 30, 2014 | 20.05 Mn |
| Jun 30, 2014 | 19.72 Mn |
| Mar 31, 2014 | 19.44 Mn |
| Dec 31, 2013 | 19.31 Mn |
| Sep 30, 2013 | 19.45 Mn |
| Jun 30, 2013 | 18.76 Mn |
| Mar 31, 2013 | 17.16 Mn |
| Dec 31, 2012 | 17.09 Mn |
| Sep 30, 2012 | 17.40 Mn |
| Jun 30, 2012 | 19.62 Mn |
| Mar 31, 2012 | 19.81 Mn |
| Dec 31, 2011 | 20.21 Mn |
| Sep 30, 2011 | 20.55 Mn |
| Jun 30, 2011 | 20.66 Mn |
| Dec 31, 2010 | 5.65 Mn |